long term response to bevacizumab to an initially
play

ESMO Preceptorship Programme Brain tumors Athens 28-29 september Tarek ASSI Institut Gustave ROUSSY - Paris Long term response to Bevacizumab to an initially resistant glioblastoma No conflict of interests ESMO PRECEPTORSHIP

0 downloads 3 Views 1,7 MB Size Report
  1. ESMO Preceptorship Programme Brain tumors – Athens – 28-29 september Tarek ASSI Institut Gustave ROUSSY - Paris Long term response to Bevacizumab to an initially resistant glioblastoma

  2.  No conflict of interests ESMO PRECEPTORSHIP PROGRAMME

  3. Initial Presentation  Age : 38 years.  History of diabetes and HTA.  December 2011: Generalized seizure.  Diagnosis of a parasagittal precentral frontal glioblastoma.  Surgery performed with complete resection of the brain tumor. ESMO PRECEPTORSHIP PROGRAMME

  4. Adjuvant Therapy  January 2012: – STUPP protocol: • Radiotherapy of 60 Gy in 30 sessions • Temozolomide 150 mg per day during radiotherapy. • Received two cycles of Temozolomide 200 mg/m2 = 400 mg for 5 days every 4 weeks – After the second cycle = A new generalized seizure. ESMO PRECEPTORSHIP PROGRAMME

  5. First relapse therapy  MRI of the brain performed: – Multinodular increased contrast enhancement in the frontal lobe region.  Decision to start Lomustine – Due to logistic issues: Procarbazine 60mg/m2 for 2 weeks every 4 weeks. • September 2012 (After 3 months), • Aphasia and somnolence • MRI : increased contrast enhancement with local frontal lobe progression. ESMO PRECEPTORSHIP PROGRAMME

  6. Second relapse therapy  Avastin 10mg/kg every 2 weeks at the dose of 770mg started on August 2012. – Initial decreased contrast enhancement with persistent response. After 4 cycles – After two years, increased proteinuria with decision to maintain Avastin at the dose of 15 mg/kg every 3 weeks – Persistent response for 3 years until September 2015 ESMO PRECEPTORSHIP PROGRAMME

  7. Therapeutic Holiday  September 2015 : Decision to start therapeutic holiday with surveillance and MRI every 3 months.  September 2016 :Maintained stable disease  MRI every 6 months.  September 2017 : memory trouble  MRI demonstrated increased contrast enhancement in the frontal lesion. ESMO PRECEPTORSHIP PROGRAMME

  8. Third Relapse  October 2017: status epilepticus – MRI : • an increased leptomeningeal contrast enhancement as well as in the superior region of the frontal lobe. – Surgery was revoked due to the multifocality of the lesions. – Admission to the critical care facility. – Right hemiplegia with conscience problems. – Improved conscience with adjustment of antiepileptic drugs.  Rechallenge with Bevacizumab 15mg/kg every 3 weeks – After two cycles in January 2018 : Persistent hemiplegia but improved clinical status with decreased contrast enhancement on MRI. ESMO PRECEPTORSHIP PROGRAMME

  9. ESMO Preceptorship Programme

Recommend Documents


long term plan the long term plan
Long Term Plan The Long Term Plan

Long Term Plan The Long Term Plan Published January 2019 Response in autumn

update
UPDATE Niraparib and

NSGO EARLY PHASE CLINICAL TRIALS UPDATE Niraparib and niraparib-bevacizumab

ercot demand response
ERCOT Demand Response Paul Wattles,

ERCOT Demand Response Paul Wattles, ERCOT Staff Long-Term Study Task Force

characterizing the long term pm 2 5 mortality response
Characterizing the long-term PM 2.5 -

Characterizing the long-term PM 2.5 - mortality response function: Comparing

preparing
Preparing Long-term Care Facilities

Preparing Long-term Care Facilities for COVID-19 Kara M. Jacobs Slifka, MD,

long term vision for larsoft overview
Long term vision for LArSoft: Overview

Long term vision for LArSoft: Overview Adam Lyon LArSoft Workshop 2019 25

covid 19 federal response
COVID-19 FEDERAL RESPONSE Leveraging

COVID-19 FEDERAL RESPONSE Leveraging federal programs for immediate relief

modeling of short term stimulation and long term
Modeling of Short-Term Stimulation and

Modeling of Short-Term Stimulation and Long-Term Operation of EGS Reservoirs

global trends our journey and response
Global trends, our journey and

TITLE: Global trends, our journey and response AUTHOR: Adrian Orr CHIEF

south burlington school district
South Burlington School District

South Burlington School District Proposed Long-Term Bond Why issue a long

recovery after stroke and
Recovery After Stroke and Genetic

Recovery After Stroke and Genetic Influences of Neuroplasticity Noel F. So,

aphasia centre of ottawa
Aphasia Centre of Ottawa Programs and

Aphasia Centre of Ottawa Programs and Services 2081 Merivale Road, suite 300

presentation presentation presentation presentation
Presentation Presentation

Presentation Presentation Presentation Presentation Presentation Abstract

stroke awareness
Stroke awareness Hannah Parrington

Stroke awareness Hannah Parrington Volunteering and Community Team- North

efficacy of language games as therapy for post stroke
Efficacy of Language Games as Therapy

Efficacy of Language Games as Therapy for Post-Stroke Aphasia Louise Lander

schizophrenia or aphasia
schizophrenia or aphasia Alex Leff

Interactive e-Therapies for patients with schizophrenia or aphasia Alex Leff

issues in single subject research
Issues In Single-Subject Research K.

Issues In Single-Subject Research K. P. Kearns ASHA CPRI 7.10.09 Data

brittany clark m s ccc slp
Brittany Clark, M.S., CCC-SLP Manager

Brittany Clark, M.S., CCC-SLP Manager of Youth & Adult Rehab

y oung ischemic stroke as presentation of thrombotic
Y oung Ischemic Stroke as Presentation

Available online at www.ijmrhs.com c a l R d i e e s M e a f o r

imaging in acute ischemic stroke
IMAGING IN ACUTE ISCHEMIC STROKE Timo

IMAGING IN ACUTE ISCHEMIC STROKE Timo Krings MD, PhD, FRCP (C) Professor of

simple and effective text simplification using semantic
Simple and Effective Text

Simple and Effective Text Simplification Using Semantic and Neural Methods

neonatal birth to age 1 month diagnosis of hhhs outcomes
Neonatal (Birth to Age 1 Month)

Title: Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome GeneReview